Targeting DNA Repair 1

AU2 AU1

Giuseppe Curigliano 2

Contents 3

1 Introduction 4
2 Hereditary Versus Sporadic Cancers 5
3 Cellular Mechanisms that Prevent or Promote Genomic Instability 6
3.1 Telomere Damage 7
3.2 Centrosomes 8
3.3 DNA Methylation and Chromatin Remodeling 9
3.4 Mitochondrial DNA Alteration in Human Cancers 10
4 DNA-Repair Pathways 11
5 Therapeutic Targeting of Genomic Instability in BC 12
6 Conclusion 13
References 14

Abstract 15

Genomic instability is a characteristic of most human cancers and plays critical 16 roles in both cancer development and progression. There are various forms of 17 genomic instability arising from many different pathways, such as DNA damage 18 from endogenous and exogenous sources, centrosome amplification, telomere 19 damage, and epigenetic modifications. DNA-repair pathways can enable tumor 20 cells to survive DNA damage. The failure to respond to DNA damage is a char- 21 acteristic associated with genomic instability. Understanding of genomic instabil- 22 ity in cancer is still very limited, but the further understanding of the molecular 23 mechanisms through which the DNA damage response (DDR) operates, in com- 24 bination with the elucidation of the genetic interactions between DDR pathways 25

Uncorrected Proof

G. Curigliano (✉)
Early Drug Development for Innovative Therapy Division, European Institute of Oncology, Via Ripamonti, 435 20141 Milan, Italy
e-mail: Giuseppe.curigliano@ieo.it

© Springer International Publishing AG 2017
Handbook of Experimental Pharmacology, DOI 10.1007/164_2017_31

and other cell pathways, will provide therapeutic opportunities for the personalized medicine of cancer.

Keywords
Cancer • DNA damage • Instability • Resistance

1 Introduction

Genomic instability is a characteristic of most human cancers and plays critical roles in both cancer development and progression.

Genomic stability is dependent on faithful DNA repair and chromosome segregation during cell division (Ferguson et al. 2015). AU3

To maintain genomic integrity, eukaryotes have evolved a system called the DNA damage response (DDR). DDR is a complex signal transduction pathway that allows cells to sense DNA damage and transduce this information to the cell to arrange the appropriate cellular responses to DNA damage (Lee et al. 2015; Ciccia and Elledge 2010). The failure to respond to DNA damage is a characteristic associated with genomic instability. This instability can manifest itself genetically on several different levels, ranging from simple DNA sequence changes to structural and numerical abnormalities at the chromosomal level. During S phase, the centrosome and genomic material are replicated concurrently, and replication errors are repaired prior to mitotic entry. During mitosis, equal segregation of chromosomes requires a bipolar mitotic spindle, telomeric preservation, and completion of the spindle assembly checkpoint. Ectopic amplification of centrosomes, telomerase dysfunction, and failure of the spindle assembly checkpoint may result in aborted mitosis. The majority of cancers exhibits chromosomal instability (CIN), which refers to the high rate by which chromosome structure and number changes over time in cancer cells compared with normal cells (Negrini et al. 2010). Although CIN is the major form of genomic instability in human cancers, other forms of genomic instability have also been described. These include accumulation of DNA base mutations and microsatellite instability (MIN), a form of genomic instability that is characterized by the expansion or contraction of the number of oligonucleotide repeats present in microsatellite sequences (Negrini et al. 2010; Lengauer et al. 1997; Fishel et al. 1993), and forms of genomic instability that are characterized by increased frequencies of base pair mutations (Leach et al. 1993). AU4

2 Hereditary Versus Sporadic Cancers

Familial breast cancer (BC) accounts for approximately 5%–10% of BC cases. The most prevalent mutations leading to hereditary breast and ovarian cancer affect the homologous recombination (HR) genes BRCA1 and BRCA2. Heterozygous individuals carrying mutations of the BRCA1 or BRCA2 genes have a 40%–80% risk of developing BC (Fackenthal and Olopade 2007).

Uncorrected Proof

Patients (pts) with BRCA2 mutations have increased incidence of male breast, pancreas, and prostate cancer (Ciccia and Elledge 2010). Tumors with BRCA1 or BRCA2 mutations are significantly associated with low level of 53BP1, indicating that 53BP1 mutation might confer a survival advantage in the absence of BRCA1 and BRCA2 (Bouwman et al. 2010). Moreover, mutations in three additional HR genes, BACH1, PALB2, and RAD51C, have been identified in approximately 3% of familial BC pts and have been associated with a twofold increased risk of BC (Levy-Lahad 2010). Mutations of CHK2, ATM, NBS1, and RAD50 have also been associated with a doubled risk of BC, indicating the importance of the ATM pathway, together with HR, in preventing BC formation. In hereditary cancers that are characterized by the presence of CIN, the genomic instability can also be attributed to mutations in DNA-repair genes. The identification of mutations in DNA-repair genes in hereditary cancers provides strong support for the *mutator hypothesis*, which states that genomic instability is present in precancerous lesions and drives tumor initiation by increasing the spontaneous mutation rate (Negrini et al. 2010; Nowell 1976; Loeb 1991). According to mutator hypothesis, the genomic instability in precancerous lesions results from mutations in caretaker genes; that is, genes that primarily function to maintain genomic stability (Negrini et al. 2010; Nowell 1976; Loeb 1991). Indeed, in inherited cancers, germline mutations targeting DNA-repair genes are present in every cell of the patient's body. Thus, a single event – loss of the remaining wild-type allele – would lead to genomic instability and drive tumor development, as predicted by the mutator hypothesis. The classical caretaker genes are DNA-repair genes and mitotic checkpoint genes (Negrini et al. 2010). Germline mutations in caretaker genes can explain the presence of genomic instability in inherited cancers. However, efforts to identify caretaker genes, the inactivation of which leads to genomic instability in sporadic (nonhereditary) cancers, have met with limited success (Negrini et al. 2010; Rajagopalan and Lengauer 2004). Thus, unlike hereditary cancers, the molecular basis of genomic instability in sporadic cancers remains unclear. A second hypothesis could explain the presence of CIN in sporadic cancers. That is, *the oncogene induced DNA replication stress model for cancer development* (Halazonetis et al. 2008; Gorgoulis et al. 2005; Bartkova et al. 2005, 2006; Di Micco et al. 2006). According to the second model, CIN in sporadic cancers results from the oncogene induced collapse of DNA replication forks, which in turn leads to DNA double-strand breaks (DSBs) and genomic instability (Negrini et al. 2010).

3 Cellular Mechanisms that Prevent or Promote Genomic Instability

3.1 Telomere Damage

Telomeres, which are located at the ends of each chromosome, consist of approximately 5–10 kbp of specialized, tandem repeat, noncoding DNA complexed with a variety of telomere associated proteins (Ferguson et al. 2015; Blackburn 2000; Greider 1991). These elements create a protective cap that prevents the recognition

Uncorrected Proof

106 of the chromosomal termini as DSBs and their consequent aberrant repair via non-
107 homologous end joining (NHEJ) or HR (Ferguson et al. 2015; Konishi and de
108 Lange 2008; Karlseder et al. 2004; Hockemeyer et al. 2005; de Lange 2010). Due to
109 the inability of DNA polymerase to fully replicate the ends of linear DNA mol-
110 ecules, in the absence of compensatory mechanisms, telomeric DNA is lost at the
111 rate of approximately 100 base pairs (bp) per telomere per cell division (Ferguson
112 et al. 2015; Harley 1991; Levy et al. 1992; Aubert and Lansdorp 2008). In normal
113 somatic cells, this telomere erosion is used by the cell to monitor its division history,
114 with moderate telomere shortening triggering either irreversible cell-cycle arrest,
115 termed replicative senescence, or apoptosis (Ferguson et al. 2015). This block to
116 continued proliferation is thought to have evolved to prevent the development of
117 cancer in long-lived organisms by restricting the uncontrolled outgrowth of trans-
118 formed cell clones, and also by preventing further telomere erosion which would
119 accompany such abnormal growth and eventually destabilize the telomeres leading
120 to CIN (Ferguson et al. 2015; Harley 1991; Harley and Sherwood 1997).

121 ## 3.2 Centrosomes

122 Centrosome amplification, the presence of greater than two centrosomes during mi-
123 tosis, is a common characteristic of most solid and hematological tumors that may
124 induce multipolar mitoses, chromosome missegregation, and subsequent genetic im-
125 balances that promote tumorigenesis (Ferguson et al. 2015; Nigg 2002).

126 The centrosome is the primary microtubule organizing center in dividing mamma-
127 lian cells (Ferguson et al. 2015). The centrosome is duplicated in a semiconservative
128 fashion with one daughter centriole formed next to a preexisting mother centriole, and
129 this process only occurs once in every cell cycle (Ferguson et al. 2015; Nigg and
130 Stearns 2011; Doxsey 2001).

131 Centrosome amplification arises from many different mechanisms, including cen-
132 trosome over duplication (Ferguson et al. 2015; Doxsey 2001; Ko et al. 2005), de
133 novo assembly (Ferguson et al. 2015; Khodjakov 2002), and mitotic failure down-
134 stream from mono- (Glover et al. 1995) or multipolar division (Maxwell et al. 2005).
135 Given that centrosome clustering may be advantageous for cancer cell survival, this
136 process may be an attractive and specific therapeutic target (Ogden et al. 2012; Gergely
137 and Basto 2008; Marthien et al. 2012). Bipolar chromosome attachment during mitosis
138 is ensured by a quality control mechanism known as the spindle assembly checkpoint
139 (Ferguson et al. 2015). The assembly checkpoint relies upon kinase signaling to delay
140 cell-cycle progression and correct attachment errors. Aurora kinase B, for example,
141 detects misattached chromosomes (Ferguson et al. 2015) and overexpression of the
142 kinase is sufficient to disrupt the checkpoint and promote tetraploidy (Ferguson et al.
143 2015). Moreover, mutations or expression changes in other checkpoint gene products
144 may compromise the checkpoint and favor tumorigenesis (Fang and Zhang 2011).

Uncorrected Proof

3.3 DNA Methylation and Chromatin Remodeling

A vast array of epigenetic mechanisms contribute to the genomic instability in cancer cells (Sharma et al. 2010). One of them is the DNA methylation, which consists of the addition of a methyl group at the carbon 5 position of the cytosine pyrimidine ring or the number 6 nitrogen of the adenine purine ring (Cedar and Bergman 2009). Most cytosine methylation occurs in the context of cytosine-phosphate-guanine (CpG) dinucleotides, and occurs via a group of DNA methyl-transferase enzymes resulting in silencing of gene transcription (Ferguson et al. 2015). A prominent example is the aberrant methylation of CpG islands in the promoter regions of DNA mismatch repair (MMR) genes that result in cancer cells with a "mutator phenotype" (Ferguson et al. 2015; Hitchins 2010). In addition to DNA methylation, histone molecules that form the primary protein component of chromatin also regulate genome stability as well as gene transcription (Sproul et al. 2005). A number of posttranslational modifications such as acetylation, deacetylation, methylation, phosphorylation, and ubiquitination have been identified that alter the function of histones (Ferguson et al. 2015). Various combinations of these posttranslational histone modifications have been hypothesized to form a "histone code" that dictates distinct chromatin structures that can affect genome stability pathways and transcription (Ferguson et al. 2015). Therefore, in most cases, histone acetylation enhances transcription while histone deacetylation represses transcription. In addition, histone acetylation can affect DNA repair. Similarly, histone ubiquitination can also modify DNA-repair capacity (Ferguson et al. 2015; Mailand et al. 2007). Finally, histone phosphorylation is an early event following DNA damage and required for efficient DNA repair (Ferguson et al. 2015).

3.4 Mitochondrial DNA Alteration in Human Cancers

Mitochondria are the key component of the oxidative phosphorylation system to generate cellular adenosine triphosphate. Mitochondrial genetic reprogramming and energy balance within cancer cells play a pivotal role in tumorigenesis (Ferguson et al. 2015). Most human cells contain hundreds of nearly identical copies of mt-DNA, which are maternally inherited. A substantial number of studies identified somatic mt-DNA mutations involving coding and noncoding mt-DNA regions in various cancers (Ferguson et al. 2015).

4 DNA-Repair Pathways

Repeated exposure to both exogenous and endogenous insults challenges the integrity of cellular genomic material. To maintain genomic integrity, DNA must be protected from damage induced by environmental agents or generated spontaneously during DNA metabolism.

Uncorrected Proof

Environmental DNA damage can be produced by physical or chemical sources. For example, the ultraviolet (UV) component of sunlight can cause up to 1 × 105 DNA lesions per cell per day, many of which are pyrimidine dimers. If left unrepaired, dimers that contain cytosine residues are prone to deamination, which can ultimately result in cytosine being replaced with thymine in the DNA sequence. Likewise, ionizing radiation (for example, from sunlight or cosmic radiation) can cause single-strand breaks (SSBs) and DSBs in the DNA double helix backbone. If misrepaired – for example, the inaccurate rejoining of broken DNA ends at DSBs, these breaks can induce mutations and lead to widespread structural rearrangement of the genome (Lord and Ashworth 2012). Table 1 (Lindahl and Barnes 2000; Hoeijmakers 2009) showed environmental agents that cause DNA damage and mutations.

Spontaneous DNA alterations can be due to dNTP misincorporation during DNA replication, interconversion between DNA bases caused by deamination, loss of DNA bases following DNA depurination, and modification of DNA bases by alkylation. Additionally, DNA breaks and oxidized DNA bases can be generated by reactive oxygen species (ROS) derived from normal cellular metabolism.

Organisms respond to chromosomal insults by activating a complex damage response pathway. This pathway regulates known responses such as cell-cycle arrest and apoptosis (programmed cell death), and has been shown to control additional processes including direct activation of DNA-repair mechanisms. Most of the subtle changes to DNA, such as oxidative lesions, alkylation products, and SSBs, are repaired through a series of mechanisms that are termed base excision repair (BER). In BER, damaged bases are first removed from the double helix, and the "injured" section of the DNA backbone is then excised and replaced with newly synthesized

Table 1 DNA lesions generated by endogenous and exogenous DNA damage (Ciccia and Elledge 2010)

AU5

Exogenous DNA damage	Dose exposure (mSV)	DNA lesions generated
Peak hour sunlight	–	Pyrimidine dimers (6–4) photoproducts
Cigarette smoke	–	DSBs
Chest X-ray	0.02	DSBs
Mammography	0.4	DSBs
Body CT scan	7	DSBs
Tumor PET scan	10	DSBs
Airline travel	0.005/h	DSBs
Endogenous DNA damage	**Dose lesions generated**	**Number of lesions/cell/day**
Depurination	AP site	10,000
Cytosine deamination	Base transition	100–500 s
SAM-induced methylation	3meA	600
	7meA	4,000
	O^6 meG	10–30
Oxidation	8oxoG	400–1,500

Uncorrected Proof

DNA (David et al. 2007). Key to this process are members of the poly(ADP-ribose) polymerase (PARP) family. The PARP family has 16 members, but only PARP1 and PARP2 have been implicated in the DDR (Schreiber et al. 2006). PARP1 and PARP2 are activated by SSBs and DSBs and catalyze the addition of poly (ADP-ribose) chains on proteins to recruit DDR factors to chromatin at breaks (Ciccia and Elledge 2010). Mispaired DNA bases are replaced with correct bases by MMR (Jirincy 2006). In addition to BER, the pool of deoxynucleotides (deoxyadenosine triphosphate (dATP), deoxythymidine triphosphate (dTTP), deoxyguanosine triphosphate (dGTP), and deoxycytidine triphosphate (dCTP)) that provide the building blocks of DNA can be chemically modified before they are incorporated into the double helix. The nucleotide pool is, therefore, continually "sanitized" by enzymes such as nudix-type motif 5 (NUDT5). Whereas small base adducts are repaired by BER, some of the bulkier single-strand lesions that distort the DNA helical structure, such as those caused by ultraviolet light, are processed by nucleotide excision repair (NER) through the removal of an oligonucleotide of approximately 30 bp containing the damaged bases. NER is often subclassified into transcription-coupled NER, which occurs where the lesion blocks, and is detected by elongating RNA polymerase, and global-genome NER, in which the lesion is detected not as part of a blocked transcription process but because it disrupts base pairing and distorts the DNA helix. Although these processes detect lesions using different mechanisms, they repair them in a similar way: DNA surrounding the lesion is excised and then replaced using the normal DNA replication machinery. Excision repair cross-complementing protein 1 (ERCC1) is the key to this excision step. The major mechanisms that cope with DSBs are HR (Moynahan and Jasin 2010) and NHEJ (Lieber 2010). HR acts mainly in the S and G2 phases of the cell cycle and is a conservative process in that it tends to restore the original DNA sequence to the site of damage. Part of the DNA sequence around the DSB is removed (known as resection) and the DNA sequence on a homologous sister chromatid is used as a template for the synthesis of new DNA at the DSB site. Crucial proteins involved in mediating HR include those encoded by the BRCA1, BRCA2, RAD51, and PALB2 genes. In contrast to HR, NHEJ occurs throughout the cell cycle. Rather than using a homologous DNA sequence to guide DNA repair, NHEJ mediates repair by directly ligating the ends of a DSB together. Sometimes this process can cause the deletion or mutation of DNA sequences at or around the DSB site. Therefore, compared with HR, NHEJ, although mechanistically simpler, can often be mutagenic.

SSBs are repaired by single-strand break repair (SSBR), whereas DSBs are processed either by NHEJ or by HR (Ciccia and Elledge 2010). DNA repair is carried out by a plethora of enzymatic activities that chemically modify DNA to repair DNA damage, including nucleases, helicases, polymerases, topoisomerases, recombinases, ligases, glycosylases, demethylases, kinases, and phosphatases.

In summary, DDR can be divided into a series of distinct, but functionally interwoven, pathways, which are defined largely by the type of DNA lesion they process (Fig. 1). DDR pathways encompass a similar set of tightly coordinated processes: namely, the detection of DNA damage, the accumulation of DNA-repair factors at the site of damage, and finally the physical repair of the lesion.

Uncorrected Proof



Fig. 1 DNA-repair mechanisms maintain genomic stability. *SSBs* single-strand breaks, *DSBs* double-strand breaks, *HR* homologous recombination, *NHEJ* nonhomologous and joining, *MMR* mismatch repair

AU6

Uncorrected Proof

251 MMR (Jirincy 2006) is crucial to the DDR. Key to the process of MMR are pro-
252 teins encoded by the mutS and mutL homologue genes, such as MSH2 and MLH1.
253 Finally, translesion synthesis and template switching allow DNA to continue to
254 replicate in the presence of DNA lesions that would otherwise halt the process.
255 Translesion synthesis and template switching are therefore usually considered to be
256 part of the DDR. In translesion synthesis, relatively high-fidelity DNA replication
257 polymerases are transiently replaced with low-fidelity "translesion" polymerases
258 that are able to synthesize DNA using a template strand encompassing a DNA le-
259 sion. Once the replication fork passes the site of the lesion, the low-fidelity DNA
260 polymerases are normally replaced with the usual high-fidelity enzyme, which al-
261 lows DNA synthesis to continue as normal. In template switching, the DNA lesion
262 is bypassed at the replication fork by simply leaving a gap in DNA synthesis op-
263 posite the lesion. After the lesion has passed the replication fork, the single-strand
264 gap is repaired using template DNA on a sister chromatid, similar to the process
265 used during HR.
266 Although sometimes considered distinct from the DDR, the mechanisms that
267 control the integrity of telomeric DNA at the end of each human chromosome also
268 act as a barrier against genomic instability and mutation (Artandi and DePinho 2010).

The core DDR machinery does not work alone but is coordinated with a set of complementary mechanisms that are also crucial to maintaining the integrity of the genome. For example, chromatin-remodeling proteins allow the DNA-repair apparatus to gain access to the damaged DNA (Bell et al. 2011). DDR core components interact with the cell-cycle checkpoint and chromosome-segregation machinery. These interactions allow DNA repair to occur before mitosis takes place and ensure that the correct complement of genetic material is passed on to daughter cells (Warmerdam and Kanaar 2010).

5 Therapeutic Targeting of Genomic Instability in BC

When as CIN, and as changes to the structure of DNA, such as nucleotide substitutions, insertions, and deletions they occur in crucial "driver" genes (of which there are probably fewer than ten per tumor), these mutations can alter cell behavior, confer a selective advantage, and drive the development of the disease. Importantly, these mutations can also influence how the tumor will respond to therapy. Alongside key driver mutations, emerging data from cancer genome sequencing suggests that a typical tumor may contain many thousands of other genetic changes. These "passenger" mutations do not contribute directly to the disease but are probably collateral damage from exposure to various environmental factors or defects in the molecular mechanisms that maintain the integrity of the genome. DNA damage causes cell-cycle arrest and cell death either directly or following DNA replication during the S phase of the cell cycle. Cellular attempts to replicate damaged DNA can cause increased cell killing, thus making DNA-damaging treatments more toxic to replicating cells than to nonreplicating cells. However, the toxicity of DNA-damaging drugs can be reduced by the activities of several DNA-repair pathways that remove lesions before they become toxic. The efficacy of DNA damage-based cancer therapy can thus be modulated by DNA-repair pathways. In addition, some of these pathways are inactivated in some cancer types. These two features make DNA-repair mechanisms a promising target for novel cancer treatments. Increasing knowledge of DNA repair permits rational combination of cytotoxic agents and inhibitors of DNA repair to enhance tumor-cell killing. Thus, DNA-repair inhibitors can be used in combination with a DNA-damaging anticancer agent. This will increase the efficiency of the cancer treatment by inhibiting DNA repair-mediated removal of toxic DNA lesions.

Moreover, DNA-repair inhibitors can be used as monotherapy to selectively kill cancer cells with a defect in the DDR or DNA repair. Synthetic lethal interactions between a tumor defect and DNA-repair pathway can be used to identify novel treatment strategies.

High levels of DNA damage cause cell-cycle arrest and cell death. Furthermore, DNA lesions that persist into the S phase of the cell cycle can obstruct replication fork progression, resulting in the formation of replication-associated DSBs. Evidence is also building that the DDR is not only invoked but also dysfunctional at an early stage in the development of neoplasia. Markers of DSBs, such as nuclear γH2AX foci (a histone phosphorylation event that occurs on chromatin surrounding

Uncorrected Proof

311 a DSB), are markedly elevated in some precancerous lesions (Halazonetis et al.
312 2008; Bartkova et al. 2006). The activation of oncogenes such as MYC and RAS
313 stimulates the firing of multiple replication forks as part of a proliferative program.
314 These forks rapidly stall, collapse, and form DSBs because they exhaust the avai-
315 lable dNTP pool or because multiple forks collide on the same chromosome. Re-
316 gardless of the mechanism, stalled and collapsed forks normally invoke the DDR
317 and cell-cycle checkpoints that enable DNA lesions to be repaired before mitosis
318 takes place. For precancerous lesions to progress to mature tumors, it is thought that
319 critical DSB signal transduction and cell-cycle checkpoint proteins, such as ataxia
320 telangiectasia (ATM) and ATM-Rad3 related (ATR), and the master "gatekeeper"
321 protein p53 become inactivated. With these DDR components rendered dysfunctional,
322 collapsed forks are not effectively repaired, and cells proceed through the cell cycle
323 with DNA lesions intact, increasing the chance of mutagenesis (Halazonetis et al.
324 2008; Bartkova et al. 2006).

325 Common types of DNA damage that interfere with replication fork progression are
326 chemical modifications (adducts) of DNA bases, which are created by reactive drugs
327 that covalently bind DNA either directly or after being metabolized in the body. These
328 ***alkylating agents*** are grouped into two categories: *monofunctional alkylating agents*
329 with one active moiety that modifies single bases and *bifunctional alkylating agents*
330 that have two reactive sites and crosslink DNA with proteins or, alternatively, cross-
331 link two DNA bases within the same DNA strand (intrastrand crosslinks) or on op-
332 posite DNA strands (interstrand crosslinks). Interstrand crosslinks pose a severe block
333 to replication forks.

334 Despite the adverse side effects caused by alkylating agents on bone marrow and
335 other normal tissues, drugs such as cyclophosphamide, ifosfamide, chlorambucil,
336 melphalan, and dacarbazine remain some of the most commonly prescribed chemo-
337 therapies in adults and children with various solid and hematological malignancies,
338 particularly in combination with anthracyclines and steroids in multi-agent regi-
339 mens. The repair of alkylated lesions is thought to be quick, with the majority of
340 lesions probably being repaired within 1 h. If the lesions are removed before the ini-
341 tiation of replication, the efficiency of alkylating agents in killing the tumor is sig-
342 nificantly reduced. Thus, modulation of DNA repair that clearly influences the efficacy
343 of alkylating agents is often explained by increased expression and/or activity of
344 DNA-repair proteins.

345 ***Antimetabolites***, such as 5-fluorouracil (5FU) and thiopurines, resemble nucleo-
346 tides, nucleotide precursors, or cofactors required for nucleotide biosynthesis and act
347 by inhibiting nucleotide metabolism pathways, thus depleting cells of dNTPs. They
348 can also impair replication fork progression by becoming incorporated into the DNA
349 (Swann et al. 1996).

350 An alternative approach of interfering with replication is to target specific DDR
351 components. Topoisomerase inhibitors, such as irinotecan (a topoisomerase I inhibitor)
352 and etoposide (a topoisomerase II inhibitor), could be considered as the first generation
353 of DDR targeted agents (Lord and Ashworth 2012). Topoisomerases are a group of
354 enzymes that resolve torsional strains imposed on the double helix during DNA trans-
355 cription and replication. They induce transient DNA breaks to relax supercoiled DNA

Uncorrected Proof

or allow DNA strands to pass through each other (Helleday et al. 2008). Etoposide and Irinotecan that inhibit this function leave DNA breaks across the genome. Topoisomerase II poisons cause DSBs, and topoisomerase I poisons cause positive supercoils in advance of replication forks and replication-associated DSBs (Helleday et al. 2008).

PARP inhibitors as targeted therapy: PARP inhibitors are the next generation of DDR inhibitors.

It has been reported that the expression levels of DNA-repair genes are frequently associated with chemotherapy sensitivity and prognosis in BC subtypes. The poly (ADP-ribose) polymerase-1 (PARP1), one of the best characterized nuclear enzymes of the 17-member PARP family, participates in the repair of DNA SSB via the BER pathway.

PARP1 and PARP2 catalyze the polymerization of ADP-ribose moieties onto target proteins (PARsylation) using NAD^+ as a substrate, releasing nicotinamide in the process. This modification often modulates the conformation, stability, or activity of the target protein (Lord and Ashworth 2012). The best understood role of PARP1 is in SSBR, a form of BER. PARP1 initiates this process by detecting and binding SSBs through a zinc finger in the PARP protein. Catalytic activity of PARP1 results in the PARsylation of PARP1 itself and the PARsylation of a series of additional proteins, such as XRCC1 and the histone H1 and H2B; when PARP activity is inhibited, SSBR is compromised (Lord and Ashworth 2012).

The PARP inhibitors have been shown a substantial efficacy for hereditary BRCA1/2-related and triple-negative BC (TNBC) therapy (Bryant et al. 2005; O'Shaughnessy et al. 2011; Zhai et al. 2015). Meanwhile, there are reports demonstrating that PARP inhibitors might be also active in nonhereditary BC cells lacking mutations in BRCA1 or BRCA2 (Zhai et al. 2015; Frizzell and Kraus 2009). From a historical perspective, PARP-1 inhibitors entered the arena as promising co-adjuvant components of standard chemo- and radiotherapy regimens. Later, the discovery that tumor-cell lines bearing deficiencies or mutation in DNA-repair genes (e.g., BRCA1 or BRCA2) do not tolerate PARP-1 inhibition fuelled the application of PARP inhibitors as single agent therapies in breast and ovarian BRCA-mutated cancer settings. More recently, the discovery of new potential combinative synergisms (e.g., PI3K, NAMPT, and EFR inhibitors) as well as the broadening of "synthetic lethality" context (e.g., PTEN and ATM mutations, MSI colorectal cancer phenotypes, and Ewing's sarcomas) in which the inhibition of PARP-1 can be therapeutically valuable has further raised interest in this target.

PARP inhibitors were designed to imitate the nicotinamide portion of NAD^+ with which they compete for the corresponding PARP-1 binding site. PARP inhibition probably works by allowing the persistence of spontaneously occurring SSBs, or by inhibiting PARP release from a DNA lesion. Whichever is the case, both of these DNA lesion types could credibly stall and collapse replication forks, potentially creating lethal DSBs (Lord and Ashworth 2012). Recent data propose an indirect mechanism, according to which PARP1 activity would be dispensable for BER sheer execution, and would be rather engaged to seize potentially detrimental SSB intermediates and to promote their resolution. Recently, PARP1 contribution to SSB repair has also been

Uncorrected Proof

401 extended to MMR and NER. In normal cells, the effects of PARP inhibition are pro-
402 tected by HR, which repairs the resultant DSB. However, effective HR is reliant on
403 functioning BRCA1 and BRCA2, so when these genes are defective – as they are in
404 tumors of germline BRCA-mutant carriers – DSBs are left unrepaired, and potent
405 PARP inhibitors can cause cell death. BRCA1 plays a role in both the G1/S and G2/M
406 cell-cycle checkpoint regulation in response to DNA damage, again preserving ge-
407 nomic integrity. Moreover, the sensitivity to PARP inhibitors seems to be defined
408 more by the BRCA genotype of a cancer cell than by its tissue of origin. Breast,
409 ovarian, and prostate cancers with BRCA mutations all seem to be profoundly sen-
410 sitive to these drugs.

411 As early as in 1980s, Durkacz and colleagues used the still immature, low-potency
412 PARP inhibitor 3-aminobenzamide (3-AB) to derail DNA damage repair and en-
413 hance the cytotoxicity of dimethyl sulfate, a DNA alkylating agent (Durkacz et al.
414 1980).

415 The first clinical trial in pts was initiated in 2003 and allowed safety, pharmaco-
416 kinetic, and pharmacodynamic evaluation of the PARP inhibitor AG014699 (*ruca-*
417 *parib* (Rouleau et al. 2010)) in combination with temozolomide (TMZ), a DNA
418 alkylator and methylator, in advanced solid tumors (Plummer et al. 2008). How-
419 ever, the subsequent phase II study in melanoma (Plummer et al. 2013), as well as
420 additional independent clinical trials, featured a common (albeit not universal)
421 shortcoming of combinatorial strategies with PARP inhibitors, namely, enhanced
422 toxicity. Myelotoxicity was the main dose-limiting concern, in the face of variable
423 response rates. The need to reduce the dosage of either chemotherapy or PARP in-
424 hibitor (or both) to overcome excessive toxicity raises obvious questions about the
425 real contribution of PARP inactivation to combinatorial regimens.

426 Currently, almost eight PARP inhibitors are at different stages of clinical in-
427 vestigation, targeting several tumor types either as single agents or in combination
428 (Table 2).

429 *Veliparib* (Veli, ABT-888) is a potent, oral inhibitor of PARP-1 and PARP-
430 2 (Penning et al. 2009). It is orally bioavailable and crosses the blood–brain barrier.
431 Veli potentiated the cytotoxic effect of TMZ in several human tumor models. ABT-
432 888 was investigated in an innovative phase 0 trial, the first such study in oncology
433 (Kummar et al. 2009). The primary study endpoint was target modulation by the
434 PARPi. There is an extensive clinical trial program associated with this agent with
435 32 ongoing clinical trials of Veli in combination with cytotoxics in ovarian, breast,
436 colorectal, prostate, liver cancers, neurologic malignancies, and leukemias. In a phase
437 2 study (Isakoff et al. 2010) combined ABT-888 and TMZ is active in metastatic BC
438 (MBC). Exploratory correlative studies including BRCA mutation analysis are un-
439 derway to determine predictors of response. The dose and schedule of Veli suggest
440 that the clinical activity seen is not likely due to Veli alone but rather to the com-
441 bination. Promising antitumor activity was observed in pts with BRCA mutations.

442 *Olaparib* (Ola, AZD2281) also inhibits PARP-1 and PARP-2 at nanomolar con-
443 centrations. Preclinical studies have largely concentrated on investigations of syn-
444 thetic lethality in BRCA1 or BRCA2 defective models or combinations with platinum
445 in these models. The first clinical study of PARP inhibition in BRCA-mutant cancers

Uncorrected Proof

Table 2 PARP inhibitors under investigation t.1

PARP inhibitor	Cancer type
Veliparib	Ovarian, breast, gastric, colorectal and pancreatic tumors and a range of other solid tumors
Niraparib (Nira, MK4827)	Ovarian cancer and BRCA+ breast cancer
Olaparib (Ola, AZD2281)	Ovarian, breast, gastric, colorectal and pancreatic tumors and a range of other solid tumors
Iniparib (BSI-201)	Breast cancer, ovarian cancer, lung cancer, glioma, glioblastoma
Rucaparib (AG014699)	Breast and other solid tumors
BMN-673	Ovarian, breast, gastric, colorectal and pancreatic tumors and a range of other solid tumors
CEP9722	Lymphoma, breast, ovarian cancer
E7016	Melanoma
AZD-2641	Solid tumors
INO-1001	Melanoma, breast cancer
E7449	Melanoma, breast cancer, ovarian, B-cell malignancies

Uncorrected Proof

was with this agent. In this phase I study which enrolled 60 pts, Ola doses were escalated from 10 mg daily for 2 of every 3 weeks to 600 mg twice daily (Fong et al. 2009). Olaparib is one of the most investigated PARP inhibitors through clinical trials either as monotherapy (Yamamoto et al. 2012; Bundred et al. 2013) or in combination with other anticancer drugs (Samol et al. 2012; Rajan et al. 2012; Dean et al. 2012; Liu et al. 2013; Dent et al. 2013; Del Conte et al. 2014). There is general agreement that 400 mg b.i.d. is the maximum tolerable dose of Ola. At this dose, Ola exhibited an acceptable safety profile. Most common adverse effects reported are of Grade 1/2 type, such as procedural pain, nausea, and other gastrointestinal symptoms of mild to moderate intensity, and thus are manageable. An important outcome of combination phase I trials results is the general tolerance of Ola when given in combination with bevacizumab (Dean et al. 2012), cediranib (Liu et al. 2013), and liposomal doxorubicin (Del Conte et al. 2014). Ola-paclitaxel combination against TNBC (Dent et al. 2013) and the Ola–CDDP combination against breast or ovarian cancer in pts carrying germline BRCA1/BRCA2 also report partial efficacy. In both studies, dose-limiting hematological toxicities were neutropenia and thrombocytopenia.

Five phase II trials were conducted with Ola alone. As with the phase I clinical trials for Ola, despite inherent differences in the study design, cancer types, patient variability, and evaluation protocols, important similarities are evident in the outcomes of these phase II clinical trials. A study in pts with confirmed BRCA1 or BRCA2 mutations and recurrent ovarian cancer (Audeh et al. 2010) yielded the objective response rate (ORR) of 33% for Ola 400 mg b.i.d. In pts with BRCA1 or BRCA2 mutations and advanced BC, ORRs were significantly higher (41%) for the 400 mg dose (Tutt et al. 2010). In another study conducted at this dose level (Gelmon et al. 2011), TNBC pts with or without BRCA mutations failed to show any objective

response (OR). Interestingly, in the same study, a very strong ORR of 41% was obtained for ovarian cancer pts with BRCA1 or BRCA2 mutations; pts without the BRCA1 or BRCA2 mutations also responded at a robust ORR of 11% (Gelmon et al. 2011). In summary in phase II clinical studies, 40% of pts with breast or ovarian cancer with germline BRCA mutations had a favorable response to the drug. This is a particularly high response given that the pts in these trials had been heavily pretreated and had become resistant to a range of chemotherapies (Lord and Ashworth 2012; Plummer et al. 2008).

INO-1001 is an isoindolinone derivative and is being developed for both oncological and cardiovascular indications. Preclinical studies demonstrate its protective effect in models of cardiac dysfunction and reversal of TMZ resistance in MMR-defective xenografts. This agent is being developed in oncology in melanoma and glioma and as a single agent in cancer for BRCA1- and BRCA2-deficient tumors. In phase I trials, INO-001 was tested alone or in combination with TMZ (Bedikian et al. 2009). Pharmacokinetic analyses indicate lack of interactions between TMZ with INO1001 and establish a "safe to administer" dose of the combination for further evaluation of the efficacy of INO1001 against advanced melanoma. However, outcomes of some clinical trials are less encouraging.

CEP9722 in phase I trials was tested alone or in combination with TMZ (Plummer et al. 2014). These dose escalation phase I trials established what the authors call an "adequately tolerated" dose for these compounds. Thus, while no neutropenia and other hematological toxicities were noticed, dose-dependent PARP inhibition was also not observed, with only limited clinical activity.

Niraparib (Nira, MK4827) is a potent inhibitor of PARP-1 and PARP-2 that is currently in phase III clinical trials for ovarian cancer and BRCA+ BC. In a phase III, randomized, open label, multicenter, controlled trial, Nira has compared versus physician's choice in previously treated, HER2 negative, germline BRCA mutation-positive BC pts. MK4827 (in a 2:1 ratio) is administered once daily continuously during a 21-day cycle. Physician's choice will be administered on a 21-day cycle. Health-related quality of life will be measured. The safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values.

Iniparib (BSI-201) is an anticancer agent with PARP inhibitory activity in preclinical models. Although the full mechanism of its antitumor activity is still under investigation, iniparib enhances the antiproliferative and cytotoxic effects of carboplatin and gemcitabine in vitro models of TNBC. Phase 1–1b studies of iniparib alone and iniparib in combination with chemotherapy in pts with advanced solid tumors have shown iniparib to have mild toxicity, with no maximal dose reached in terms of side effects. O'Shaughnessy et al. (2011), in a phase II trial, evaluate whether iniparib could potentiate the antitumor effects of gemcitabine and carboplatin with acceptable toxicity levels. A total of 123 pts were randomly assigned to receive gemcitabine (1,000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration–time curve of 2) on days 1 and 8 – with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11 – every 21 days. Primary end points were the rate of clinical benefit (CB) (i.e.,

Uncorrected Proof

the rate of OR [complete or partial response] plus the rate of stable disease (SD) for ≥6 months) and safety. Additional end points included the ORR, progression-free survival (PFS), and overall survival (OS). The addition of iniparib to chemotherapy improved the CB and OS of pts with metastatic TNBC without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted.

In summary, there are many differences in the studies evaluating anticancer activity of PARP inhibitors used alone or in combination with one or more anticancer agents. While there are many differences in the studies, some common observations should be noted with particular emphasis on various enzymatic activities associated with this multi-domain group of proteins as it applies to developing new anticancer agents and/or regimens. Specifically, the discovery of activation of PARP-2 and PARP-3 by phosphorylated DNA ends mimicking substrates or intermediates in various DNA-repair pathways is quite important. These observations shed new light on the molecular functions of different PARPs. Additionally, better understanding of the substrate specificity of individual members of the PARP family will allow researchers to further refine inhibitor chemistry and minimize adverse effects of drugs currently under evaluation. Another area of considerable potential for research and development of PARP inhibitors as first-line anticancer drugs is their application to personalized medicine. Targeted therapy is rapidly becoming a hallmark of a number of anticancer drugs.

Platinum chemotherapies: cisplatin, carboplatin, and oxaliplatin have become three of the most commonly prescribed chemotherapeutic drugs used to treat solid cancers in pts (Helleday et al. 2008). Platinum resistance, either intrinsic or acquired during cyclical treatment, is a major clinical problem as additional agents that can be added to therapy in order to circumvent tumor resistance do not currently exist. Platinum chemotherapy is now being tested with PARP inhibition clinical trials. The rationale for combining PARP inhibition with platinum chemotherapy is based on preclinical observations that PARP inhibitors preferentially kill neoplastic cells and induce complete or partial regression of a wide variety of human tumor xenografts in nude mice treated with platinum chemotherapy (Helleday et al. 2008). For example, Veli has been shown to potentiate the regression of established tumors induced by cisplatin, carboplatin therapy in rodent orthotopic and xenografts models (Helleday et al. 2008). However, the biological mechanisms of chemo-sensitization of cancer cells to platinum chemotherapy by PARP inhibition remain to be resolved.

Ionizing radiation and radiomimetic agents such as bleomycin cause replication-independent DSBs that can kill nonreplicating cells. In addition, such treatments can also rapidly prevent DNA replication by activation of cell-cycle checkpoints to avoid formation of toxic DNA replication lesions (Helleday et al. 2008).

Targeting microsatellite instability (MSI). MSI is a marker of defective MMR. The predictive value of MMR status as a marker of response to 5FU, irinotecan, and other drugs is still controversial. Two large retrospective analyses from several randomized trials confirmed the detrimental effect of a 5FU-based adjuvant therapy in stage II colorectal patients (Bedikian et al. 2009), not applicable to stage III patients (Plummer et al. 2014). These latter authors, however, reported that MSI stage III

Uncorrected Proof

561 tumors harboring genetic mutation in the MMR genes seem to benefit from the 5FU
562 adjuvant therapy. These data imply that molecular differences within the MSI sub-
563 group influence the response to 5FU. Combination therapy with methotrexate (MTX)
564 and PARP inhibitors may be effective against tumors with MMR mutations. MTX
565 elevates ROS and DSBs and the combination of MMR mutation and PARP inhibition
566 may attenuate repair and induce growth arrest or apoptosis (McCabe et al. 2006; Vilar
567 et al. 2011; Miquel et al. 2007).

568 ***Targeting gene expression of cell cycle and DNA-repair components***: Resver-
569 atrol, a phytoalexin produced by plants such as the Japanese knotweed, prevents
570 hypermethylation of the BRCA1 promoter (Papoutsis et al. 2012), and maybe ef-
571 fective for TNBC or basal subtype BC. Other natural compounds, like genistein and
572 lycopene, can alter DNA methylation of the glutathione S transferase p1 (GSTP1)
573 tumor suppressor gene.

574 ***Targeting centrosome abnormalities***: griseofulvin, an antifungal drug that sup-
575 presses proliferation in tumor cells without affecting non-transformed cells, declusters
576 centrosome, although the precise mechanisms behind the drug's action remain un-
577 known (Ogden et al. 2012). In a similar fashion, depletion of a kinesin-like motor
578 protein can selectively kill tumor cells with supernumerary centrosomes (Ogden et al.
579 2012). Finally, the PARP inhibitor PJ34 also declusters super numerary centrosomes
580 without deleterious effects on spindle morphology, centrosome integrity, mitosis, or
581 cell viability in normal cells (Kwon et al. 2008).

582 6 Conclusion

583 Genomic instability plays a critical role in cancer initiation and progression. The
584 fidelity of the genome is protected at every stage of the cell cycle. In cancer, the
585 presence of aneuploid or tetraploid cells indicates the failure of one or many of
586 these safety nets. The resultant genomic heterogeneity may offer the cancer "tissue"
587 a selection advantage against standard of care and emerging therapies. Understand-
588 ing these safety nets, and how they are bypassed in cancer cells, may highlight
589 new and more specific mechanisms for cancer prevention or therapeutic attack. The
590 therapeutic targeting of genomic instability may check and inhibit other enabling
591 characteristic of tumors cells, such as replicative immortality, evasion of antigrowth
592 signaling, and tumor promoting inflammation. To this end, vitamins, minerals, and
593 antioxidants, such as vitamin B, vitamin D, carotenoids, and selenium, as well as
594 nutraceuticals, such as resveratrol, have shown remarkable plasticity in elucidating
595 antitumor responses. In addition to alleviating genomic instability, these compounds
596 are known to inhibit proliferative signaling, attenuate oncogenic metabolism, and
597 block inflammation.

Uncorrected Proof

References

Artandi SE, DePinho RA (2010) Telomeres and telomerase in cancer. Carcinogenesis 31:9–18

Aubert G, Lansdorp PM (2008) Telomeres and aging. Physiol Rev 88:557–579

Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–251

Bartkova J, Hořejší Z, Koed K et al (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864–870

Bartkova J, Rezaei N, Liontos M et al (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444:633–637

Bedikian AY, Papadopoulos NE, Kim KB et al (2009) A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 27:756–763

Bell O, Tiwari VK, Thoma NH, Schubeler D (2011) Determinants and dynamics of genome accessibility. Nat Rev Genet 12:554–564

Blackburn EH (2000) Telomeres and telomerase. J Med 49:59–65

Bouwman P, Aly A, Escandell JM et al (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17:688–695

Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917

Bundred N, Gardovskis J, Jaskiewicz J et al (2013) Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicenter trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 31:949–958

Castiel A, Visochek L, Mittelman L et al (2011) Aphenanthrene derived PARP inhibitor is an extra-centrosomes declustering agent exclusively eradicating human cancer cells. BMC Cancer 11:412

Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10:295–304

Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40:179–204

David SS, O’Shea VL, Kundu S (2007) Base-excision repair of oxidative DNA damage. Nature 447:941–950

de Lange T (2010) How shelterin solves the telomere end-protection problem. Cold Spring Harb Symp Quant Biol 75:167–177

Dean E, Middleton MR, Pwint T et al (2012) Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 106:468–474

Del Conte G, Sessa C, von Moos R et al (2014) Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer 111:651–659

Dent RA, Lindeman GJ, Clemons M et al (2013) Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 15:R88

Di Micco R, Fumagalli M, Cicalese A et al (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyperreplication. Nature 444:638–642

Doxsey S (2001) Re-evaluating centrosome function. Nat Rev Mol Cell Biol 2:688–698

Durkacz BW, Omidiji O, Gray DA, Shall S (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283:593–596

Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937–948

Fang X, Zhang R (2011) Aneuploidy and tumourigenesis. Semin Cell Dev Biol 22:595–601

Uncorrected Proof

648 Ferguson LR, Chen H, Collins AR et al (2015) Genomic instability in human cancer: molecular
649 insights and opportunities for therapeutic attack and prevention through diet and nutrition.
650 Semin Cancer Biol 35:S5–S24
651 Fishel R, Lescoe MK, Rao MRS, Copeland NG (1993) The human mutator gene homolog MSH2
652 and its association with hereditary non-polyposis colon cancer. Cell 75:1027–1038
653 Fong PC, Yap TA, Boss DS et al (2009) Poly(ADP)-ribose polymerase inhibition: frequent durable
654 responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol
655 28:2512–2519
656 Frizzell KM, Kraus WL (2009) PARP inhibitors and the treatment of breast cancer: beyond
657 BRCA1/2? Breast Cancer Res 11:111
658 Gelmon KA, Tischkowitz M, Mackay H et al (2011) Olaparib in patients with recurrent high-grade
659 serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase
660 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852–861
661 Gergely F, Basto R (2008) Multiple centrosomes: together they stand, divided they fall. Genes Dev
662 22:2291–2296
663 Glover DM, Leibowitz MH, McLean DA et al (1995) Mutations in aurora prevent centrosome
664 separation leading to the formation of monopolar spindles. Cell 891:95–105
665 Gorgoulis VG, Vassiliou LVF, Karakaidos P et al (2005) Activation of the DNA damage
666 checkpoint and genomic instability in human precancerous lesions. Nature 434:907–913
667 Greider CW (1991) Telomeres. Curr Opin Cell Biol 3:444–451
668 Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for
669 cancer development. Science 319:1352–1355
670 Harley CB (1991) Telomere loss: mitotic clock or genetic time bomb. Mutat Res 256:271–282
671 Harley CB, Sherwood SW (1997) Telomerase, checkpoints and cancer. Cancer Surv 29:263–284
672 Helleday T, Petermann E, Lundin C et al (2008) DNA repair pathways as targets for cancer
673 therapy. Nat Rev Cancer 8:193–204
674 Hitchins MP (2010) Inheritance of epigenetic aberrations (constitutional epimutations) in cancer
675 susceptibility. Adv Genet 70:201–243
676 Hockemeyer D, Sfeir AJ, Shay JW et al (2005) POT1 protects telomeres from a transient DNA
677 damage response and determines how human chromosomes end. EMBO J 24:2667–2678
678 Hoeijmakers JH (2009) DNA damage, aging, and cancer. N Engl J Med 361:1475–1485
679 Isakoff SJ, Overmoyer B, Tung NM et al (2010) A phase II trial of the PARP inhibitor veliparib
680 (ABT888) and temozolomide for metastatic breast cancer. ASCO annual meeting abstracts. J
681 Clin Oncol 28(15_suppl):1019
682 Jirincy J (2006) The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7:335–346
683 Karlseder J, Hoke K, Mirzoeva OK et al (2004) The telomeric protein TRF2 binds the ATM kinase
684 and can inhibit the ATM-dependent DNA damage response. PLoS Biol 2:E240
685 Khodjakov A (2002) De novo formation of centrosomes in vertebrate cells arrested during S phase.
686 J Cell Biol 158:1171–1181
687 Ko MA, Rosario CO, Hudson JW et al (2005) Plk4 haploinsufficiency causes mitotic infidelity and
688 carcinogenesis. Nat Genet 37:883–888
689 Konishi A, de Lange T (2008) Cell cycle control of telomere protection and NHEJ revealed by a ts
690 mutation in the DNA-binding domain of TRF2. Genes Dev 22:1221–1230
691 Kummar S, Kinders R, Gutierrez ME et al (2009) Phase 0 clinical trial of the poly (ADP-ribose)
692 polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol
693 27:2705–2711
694 Kwon M, Godinho SA, Chandhok NS et al (2008) Mechanisms to suppress multipolar divisions in
695 cancer cells with extra centrosomes. Genes Dev 22:2189–2203
696 Leach FS, Nicolaides NC, Papadopoulos N, Liu B (1993) Mutations of a mutS homolog in
697 hereditary non-polyposis colorectal cancer. Cell 75:1215–1225
698 Lee JH, Jeong SY, Kim MJ et al (2015) MicroRNA-22 suppresses DNA repair and promotes
699 genomic instability through targeting of MDC1. Cancer Res 75:1298

Uncorrected Proof

Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386:623–627 700 701
Levy MZ, Allsopp RC, Futcher AB et al (1992) Telomere end-replication problem and cell aging. J Mol Biol 225:951–960 702 703
Levy-Lahad E (2010) Fanconi anemia and breast cancer susceptibility meet again. Nat Genet 42:368–369 704 705
Lieber MR (2010) NHEJ and its backup pathways in chromosomal translocations. Nat Struct Mol Biol 17:393–395 706 707
Lindahl T, Barnes DE (2000) Repair of endogenous DNA damage. Cold Spring Harb Symp Quant Biol 65:127–133 708 709
Liu JF, Tolaney SM, Birrer M et al (2013) A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 49:2972–2978 710 711 712
Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075–3079 713 714
Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481:287 715
Mailand N, Bekker-Jensen S, Faustrup H et al (2007) RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131:887–900 716 717
Marthien V, Piel M, Basto RJ (2012) Never tear us apart – the importance of centrosome clustering. Cell Sci 125:3281–3292 718 719
Maxwell CA, Keats JJ, Belch AR et al (2005) Receptor forhyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res 56:850–860 720 721 722
McCabe N, Turner NC, Lord CJ et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109–8115 723 724 725
Miquel C, Jacob S, Grandjouan S et al (2007) Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 26:5919–5926 726 727 728
Moynahan ME, Jasin M (2010) Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 11:196–207 729 730
Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability – an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11:220–228 731 732
Nigg EA (2002) Centrosome aberrations: cause or consequence of cancer progression. Nat Rev Cancer 2:815–825 733 734
Nigg EA, Stearns T (2011) The centrosome cycle: centriole biogenesis, duplication and inherent asymmetries. Nat Cell Biol 13:1154–1160 735 736
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28 737
O'Shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205–214 738 739
Ogden A, Rida PC, Aneja R (2012) Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy. Cell Death Differ 19:1255–1267 740 741 AU8
Papoutsis AJ, Borg JL, Selmin OI, Romagnolo DF (2012) BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells. J Nutr Biochem 23:1324–1332 742 743 744
Penning TD, Zhu GD, Gandhi VB et al (2009) Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-Yl]-1h-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52:514–523 745 746 747
Plummer R, Jones C, Middleton M et al (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14:7917–7923 748 749 750

Uncorrected Proof

751 Plummer R, Lorigan P, Steven N et al (2013) A phase II study of the potent PARP inhibitor,
752 Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma
753 demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 71:1191–1199
754 Plummer R, Stephens P, Aissat-Daudigny L et al (2014) Phase 1 dose escalation study of the PARP
755 inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with
756 solid tumors. Cancer Chemother Pharmacol 74:257–265
757 Rajagopalan H, Lengauer C (2004) Aneuploidy and cancer. Nature 432:338–341
758 Rajan A, Carter CA, Kelly RJ et al (2012) A phase I combination study of olaparib with cisplatin
759 and gemcitabine in adults with solid tumors. Clin Cancer Res 18:2344–2351
760 Rouleau M, Patel A, Hendzel MJ et al (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer
761 10:293–301
762 Samol J, Ranson M, Scott E et al (2012) Safety and tolerability of the poly(ADP-ribose) poly-
763 merase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment
764 of patients with advanced solid tumors: a phase I study. Invest New Drugs 30:1493–1500
765 Sargent DJ, Marsoni S, Monges G et al (2010) Defective mismatch repair as a predictive marker
766 for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol
767 28:3219–3226
768 Schreiber V, Dantzer F, Ame JC, de Murcia G (2006) Poly(ADPribose): novel functions for an old
769 molecule. Nat Rev Mol Cell Biol 7:517–528
770 Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27–36
771 Sinicrope FA, Foster NR, Thibodeau SN et al (2011) DNA mismatch repair status and colon
772 cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl
773 Cancer Inst 103:863–875
774 Sproul D, Gilbert N, Bickmore WA (2005) The role of chromatin structure in regulating the
775 expression of clustered genes. Nat Rev Genet 6:775–781
776 Swann PF, Waters TR, Moulton DC (1996) Role of postreplicative DNA mismatch repair in the
777 cytotoxic action of thioguanine. Science 273:1109–1111
778 Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in
779 patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept
780 trial. Lancet 376:235–244
781 Vilar E, Bartnik CM, Stenzel SL et al (2011) MRE11 deficiency increases sensitivity to poly
782 (ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res
783 71:2632–2642
784 Warmerdam DO, Kanaar R (2010) Dealing with DNA damage: relationships between checkpoint
785 and repair pathways. Mutat Res 704:2–11
786 Yamamoto N, Nokihara H, Yamada Y et al (2012) A phase I, dosefinding and pharmacokinetic
787 study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci
788 103:504–509
789 Zhai L, Li S, Li X et al (2015) The nuclear expression of poly (ADP-ribose) polymerase-1
790 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity. Pathol
791 Res Pract 211:130–137

AU10
AU9

Uncorrected Proof

Author Queries

Chapter No.: 31

Query Refs.	Details Required	Author's response
AU1	Please verify the inserted email address of the corresponding author.	
AU2	Please check if the presentation of the affiliation is fine.	
AU3	Please note that the reference style has been changed from Numbered style to Name–Date style as per the style.	
AU4	Please note that the term "microsatellite instability" has been abbreviated both as "MIN" and as "MSI". Kindly check and amend if it has to be made consistent.	
AU5	Please check the presentation of Table 1 and amend if necessary.	
AU6	Footnote present in the artwork of "Fig. 1" has been moved to its figure caption as per style. Please check.	
AU7	Please check the sentence "When as CIN, and as changes to . . ." for clarity.	
AU8	Reference "Ogden et al. 2012 (originally in MS Refs. [36] and [87])" was found repeated twice, hence the latter has been removed from the reference list and the citations have been updated accordingly. Please check.	
AU9	As there were two set of references for "Refs. [81] and [82] (originally in MS)", the references have been renumbered as follows: [81] → [83], [82] → [84], [83] → [85], [84] → [86], [85] → [87], [86] → [88], [87] → [89], [88] → [90], [89] → [91].	
AU10	Please cite the references "Sargent et al. 2010 and Sinicrope et al. 2011 ([second set of] Refs. [81] and [82] in MS)" and reference "Castiel et al. 2011 (Ref. [89] in MS)" in the text or delete them from the reference list.	

Uncorrected Proof